secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014811
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q2 revenue $125.3M; core revenue up 102% YoY, guidance raised
------------------------------------------------------------------------------

- Total revenue $125.3M (Q2 2021: $153.6M); billable tests 1.3M (vs 1.6M).
- Core revenue (ex-COVID) $45.3M, +102% YoY; full-year core revenue guidance raised to $185M from $180M.
- GAAP net income $11.5M ($0.37/share); non-GAAP net income $24.3M ($0.78/share); adjusted EBITDA $37.7M.
- Cash & marketable securities $931M as of June 30, 2022.
- Strong growth in genetic testing beyond COVID driving core revenue expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022014811/0000950170-22-014811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022014811/flgt-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer